CA3171025A1 - Ligands de proteine d'activation des fibroblastes pour applications d'administration ciblee - Google Patents

Ligands de proteine d'activation des fibroblastes pour applications d'administration ciblee

Info

Publication number
CA3171025A1
CA3171025A1 CA3171025A CA3171025A CA3171025A1 CA 3171025 A1 CA3171025 A1 CA 3171025A1 CA 3171025 A CA3171025 A CA 3171025A CA 3171025 A CA3171025 A CA 3171025A CA 3171025 A1 CA3171025 A1 CA 3171025A1
Authority
CA
Canada
Prior art keywords
moiety
cancer
compound
conjugate
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171025A
Other languages
English (en)
Inventor
Ilaria BIANCOFIORE
Samuele CAZZAMALLI
Sheila Dakhel Plaza
Etienne J. DONCKELE
Jacopo MILLUL
Florent SAMAIN
Eleonore SCHMIDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philochem AG
Original Assignee
Philochem AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philochem AG filed Critical Philochem AG
Priority claimed from PCT/EP2021/053494 external-priority patent/WO2021160825A1/fr
Publication of CA3171025A1 publication Critical patent/CA3171025A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des ligands de la protéine d'activation des fibroblastes (FAP) pour l'administration active de diverses charges utiles (par exemple, des médicaments cytotoxiques, des radionucléides, des fluorophores, des protéines et des immunomodulateurs) au niveau du site de maladie. En particulier, la présente invention concerne le développement de ligands FAP pour des applications de ciblage, notamment des méthodes et/ou des méthodes de diagnostic pour une thérapie ou une chirurgie par rapport à une maladie ou un trouble, tel qu'un cancer, une inflammation ou une autre maladie caractérisée par la surexpression de FAP.
CA3171025A 2020-02-12 2021-02-12 Ligands de proteine d'activation des fibroblastes pour applications d'administration ciblee Pending CA3171025A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20157036.3 2020-02-12
EP20157036 2020-02-12
EP20172953.0 2020-05-05
EP20172953 2020-05-05
EP20202856.9 2020-10-20
EP20202856 2020-10-20
PCT/EP2021/053494 WO2021160825A1 (fr) 2020-02-12 2021-02-12 Ligands de protéine d'activation des fibroblastes pour applications d'administration ciblée

Publications (1)

Publication Number Publication Date
CA3171025A1 true CA3171025A1 (fr) 2021-08-19

Family

ID=83225945

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171025A Pending CA3171025A1 (fr) 2020-02-12 2021-02-12 Ligands de proteine d'activation des fibroblastes pour applications d'administration ciblee

Country Status (8)

Country Link
JP (1) JP2023514275A (fr)
KR (1) KR20220154111A (fr)
CN (1) CN115335370A (fr)
AU (1) AU2021220663A1 (fr)
BR (1) BR112022016049A2 (fr)
CA (1) CA3171025A1 (fr)
IL (1) IL295571A (fr)
MX (1) MX2022009931A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925041A (zh) * 2023-06-12 2023-10-24 上海交通大学医学院附属仁济医院 靶向成纤维细胞激活蛋白的氟标记放射性药物前体、放射性标记化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118932A1 (fr) * 2017-12-15 2019-06-20 Praxis Biotech LLC Inhibiteurs de la protéine d'activation des fibroblastes
JP2021512949A (ja) * 2018-02-06 2021-05-20 ウニベルジテート ハイデルベルク Ｆａｐ阻害物質

Also Published As

Publication number Publication date
BR112022016049A2 (pt) 2022-11-16
IL295571A (en) 2022-10-01
JP2023514275A (ja) 2023-04-05
AU2021220663A1 (en) 2022-10-06
CN115335370A (zh) 2022-11-11
MX2022009931A (es) 2022-09-12
KR20220154111A (ko) 2022-11-21

Similar Documents

Publication Publication Date Title
EP3891138B1 (fr) Ligands de protéines d'activation de fibroblastes pour des applications d'administration ciblées
US20230381324A1 (en) Small molecule drug conjugates
RU2714933C2 (ru) Конъюгаты var2csa-лекарственное средство
US20240148916A1 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
EP4043452A1 (fr) Ligands de protéines d'activation de fibroblastes bivalents pour des applications d'administration ciblées
WO2023144379A1 (fr) Ligands à haute affinité de protéine d'activation des fibroblastes pour des applications d'administration ciblée
CA3171025A1 (fr) Ligands de proteine d'activation des fibroblastes pour applications d'administration ciblee
US20230147962A1 (en) Fibroblast activation protein ligands for targeted delivery applications
CA3198066A1 (fr) Conjugues reactifs
WO2024094827A1 (fr) Ligands d'anhydrase carbonique ix pour applications par administration ciblée
CN116917278A (zh) 用于靶向递送应用的二价成纤维细胞活化蛋白配体
WO2024052333A1 (fr) Ligands multivalents de protéine d'activation des fibroblastes pour applications d'administration ciblée
WO2023088236A1 (fr) Ligand peptidique bicyclique de mt1-mmp et son conjugué
EA046139B1 (ru) Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b